Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphomaWyndham H. Wilson, Louis M. Staudt, Sven de Vos et al.|Nature Medicine|2015Cited by 1.1k
Effect of Capivasertib in Patients With an <i>AKT1 E17K</i>-Mutated TumorKevin Kalinsky, Keith T. Flaherty, Fangxin Hong et al.|JAMA Oncology|2020Cited by 106
Crizotinib in patients with tumors harboring ALK or ROS1 rearrangements in the NCI-MATCH trialAaron S. Mansfield, Keith T. Flaherty, Zihan Wei et al.|npj Precision Oncology|2022Cited by 42
Erdafitinb in patients with FGFR-altered tumors: Results from the NCI-COG Pediatric MATCH trial arm B (APEC1621B).Alice A. Lee, D. Williams Parsons, Alexander J. Chou et al.|Journal of Clinical Oncology|2023Cited by 18
Phase II Study of Erdafitinib in Patients With Tumors With <i>FGFR</i> Amplifications: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol K1Jun Gong, Keith T. Flaherty, Alain C. Mita et al.|JCO Precision Oncology|2024Cited by 16